UniProt/SwissProt ID: | GSTP1_HUMAN |
Description: | glutathione S-transferase pi 1 [Source:HGNC Symbol;Acc:4638] |
Location: | chr11 q13.2 |
Node attribute: | ligand |
Phosphorylation site |
Position | PhosphoPeptide | Catalytic kinase | Source |
---|---|---|---|
Y112 | LIYTNyEAGKD | GST_C | PhosphoSitePlus |
S43 | TWQEGsLKASC | GST_N | PhosphoSitePlus |
Y199 | LASPEyVNLPI | PhosphoSitePlus | |
S43 | TWQEGsLKASC | HPRD | |
T62 | QDGDLtLYQSN | GST_N | PhosphoSitePlus |
Y50 | KASCLyGQLPK | GST_N | PhosphoSitePlus |
S185 | YVGRLsARPKL | GST_C | PhosphoSitePlus |
Y8 | PYTVVyFPVRG | GST_N | PhosphoSitePlus |
Y109 | YISLIyTNYEA | GST_C | PhosphoSitePlus |
S135 | FETLLsQNQGG | GST_C | PhosphoSitePlus |
T110 | ISLIYtNYEAG | GST_C | PhosphoSitePlus |
Y4 | __MPPyTVVYF | GST_N | PhosphoSitePlus |
Y64 | GDLTLyQSNTI | GST_N | PhosphoSitePlus |
Y80 | RTLGLyGKDQQ | PhosphoSitePlus | |
Dephosphorylation site |
GSTP1_HUMAN do not have dephosphorylation site. |
Mutation site |
GSTP1_HUMAN do not have mutation site. |
Differential expressed protein |
Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
---|---|---|---|---|---|---|
ENSP00000381607 | Ovarian Cancer | Treatment (cisplatin-sensitive vs. cisplatin-resistant) | cell line | Up | 3.2 | 16319398 |
ENSP00000381607 | Leukemia | Normal vs. Cancer | cell line | Down | 0.28 | 17022645 |
ENSP00000381607 | Leukemia | Normal vs. Cancer | cell line | Up | 24 | 17022645 |
ENSP00000381607 | Thyroid Carcinoma | Normal vs. Cancer | tissue | Up | 5.2 | 17194741 |
ENSP00000381607 | Prostate Cancer | Metastasis | tissue | Down | 0.29 | 18553995 |
ENSP00000381607 | Breast Cancer | Metastasis | tissue | Up | 2.1 | 19053527 |
ENSP00000381607 | Oral Cancer | Normal vs. Cancer | tissue | Up | 2.5 | 16889763 |
ENSP00000381607 | Melanoma | Treatment (none vs. metastasis suppressor 1 (BRMS1) overEXPressed) | cell line | Down | 0.48 | 17854218 |
ENSP00000381607 | Hepatocellular Carcinoma | Treatment (none vs. Suberonylanilide hydroxamic acid (SAHA) treatment) | tissue | Down | 17593366 | |
ENSP00000381607 | hepatitis B virus | Normal vs. Cancer | tissue | Up | 3.2 | 17671684 |
ENSP00000381607 | Neoplasms by Histologic Type | Normal vs. Cancer | tissue | Up | 3 | 12874873 |
ENSP00000381607 | Non-small cell lung carcinoma | Metastasis | cell line | Down | 17418446 | |
ENSP00000381607 | Lung Cancer | Treatment (none vs. Mitoxantrone resistance) | cell line | Up | 1.8 | 17593620 |
ENSP00000381607 | Non-small cell lung carcinoma | Treatment (none vs CIGB-300 treatment) | cell line | Down | 0.1 | 20804217 |
ENSP00000381607 | Non-small cell lung carcinoma | Treatment (none vs CIGB-300 treatment) | cell line | Down | 0.32 | 20804217 |
ENSP00000381607 | Gastric Cancer | Normal vs. Cancer | tissue | Down | 14711373 | |
ENSP00000381607 | Gastric Cancer | Treatment (none vs. drug-resistant) | cell line | Down | 18309519 | |
ENSP00000381607 | Breast Cancer | Metastasis | cell line | Up | 4.7 | 18582095 |
ENSP00000381607 | Breast Cancer | Metastasis | cell line | Down | 0.49 | 18582095 |
ENSP00000381607 | Breast Cancer | Treatment (TNF-a-sensitive vs. TNF-a-resistant ) | cell line | Up | 5.4 | 19087274 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | tissue | Up | 2.4 | 20005186 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.076 | 20052998 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.18 | 20052998 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.075 | 20052998 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.22 | 20052998 |
ENSP00000381607 | Breast Cancer | Metastasis | cell line | Up | 1 | 20052998 |
ENSP00000381607 | Breast Cancer | Metastasis | cell line | Up | 1.3 | 20052998 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.036 | 20052998 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.058 | 20052998 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.086 | 20052998 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.11 | 20052998 |
ENSP00000381607 | Breast Cancer | Metastasis | cell line | Up | 2.1 | 20052998 |
ENSP00000381607 | Breast Cancer | Metastasis | cell line | Up | 2.4 | 20052998 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.03 | 20198662 |
ENSP00000381607 | breast ductal carcinoma | Normal vs. Cancer | tissue | Down | 0.013 | 20534901 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | tissue | Down | 20560667 | |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | tissue | Down | 0.92 | 20739354 |
ENSP00000381607 | Breast Cancer | Normal vs. Cancer | tissue | Down | 0.92 | 20739354 |
ENSP00000381607 | Oral Cancer | Normal vs. Cancer | tissue | Up | 5.4 | 19691830 |
ENSP00000381607 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | 6.6 | 17655343 |
ENSP00000381607 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | 20 | 17655343 |
ENSP00000381607 | acute myeloid leukemia | Treatment (none vs. NSC606985 treatment) | cell line | Up | 8.3 | 17655343 |
ENSP00000381607 | Neoplasms by Histologic Type | Treatment (none vs. SB203580 treatment 21 hour) | cell line | Down | 0.45 | 15169874 |
ENSP00000381607 | Uterine Cancer | Treatment(none vs. transfected with the pOP13 vector that containing E7) | cell line | Down | 14997504 | |
ENSP00000381607 | Gastric Cancer | Normal vs. Cancer | tissue | Down | 0.43 | 15761955 |
ENSP00000381607 | Uterine Cancer | Normal vs. Cancer | tissue | Up | 16051329 | |
ENSP00000381607 | Uterine Cancer | Normal vs. Cancer | tissue | Up | 19771267 | |
Hyperphosphorylation site |
GSTP1_HUMAN do not have hyperphosphorylation site. |
Direct Interaction Pair |
Source | Target | Relationship | Resource |
---|---|---|---|
GSTP1_HUMAN | TRAF2_HUMAN | ligand -> receptor | HPMR |
Function Annotation |
KEGG Pathway |
KEGG ID | Pathway |
---|---|
hsa05200 | Pathways in cancer |
hsa00480 | Glutathione metabolism |
hsa00982 | Drug metabolism - cytochrome P450 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450 |
hsa05215 | Prostate cancer |
Gene Ontology |
GO ID | GO_Term | Evidence | Ontology |
---|---|---|---|
GO:0006805 | xenobiotic metabolic process | IDA | biological_process |
GO:0032691 | negative regulation of interleukin-1 beta producti | IDA | biological_process |
GO:0002674 | negative regulation of acute inflammatory response | NAS | biological_process |
GO:0006469 | negative regulation of protein kinase activity | IDA | biological_process |
GO:0060547 | negative regulation of necrotic cell death | ISS | biological_process |
GO:0043409 | negative regulation of MAPK cascade | NAS | biological_process |
GO:0071638 | negative regulation of monocyte chemotactic protei | IDA | biological_process |
GO:0006749 | glutathione metabolic process | IDA | biological_process |
GO:0097057 | TRAF2-GSTP1 complex | IDA | cellular_component |
GO:0043508 | negative regulation of JUN kinase activity | IDA | biological_process |
GO:0070664 | negative regulation of leukocyte proliferation | ISS | biological_process |
GO:0071222 | cellular response to lipopolysaccharide | ISS | biological_process |
GO:0019207 | kinase regulator activity | ISS | molecular_function |
GO:0070372 | regulation of ERK1 and ERK2 cascade | ISS | biological_process |
GO:0032873 | negative regulation of stress-activated MAPK casca | ISS | biological_process |
GO:0048147 | negative regulation of fibroblast proliferation | ISS | biological_process |
GO:0043066 | negative regulation of apoptotic process | IDA | biological_process |
GO:0010804 | negative regulation of tumor necrosis factor-media | IC | biological_process |
GO:0005737 | cytoplasm | TAS | cellular_component |
GO:0035730 | S-nitrosoglutathione binding | IDA | molecular_function |
GO:0005739 | mitochondrion | IEA | cellular_component |
GO:0008432 | JUN kinase binding | ISS | molecular_function |
GO:0009890 | negative regulation of biosynthetic process | IDA | biological_process |
GO:0004364 | glutathione transferase activity | IDA | molecular_function |
GO:0032720 | negative regulation of tumor necrosis factor produ | IDA | biological_process |
GO:0005622 | intracellular | IDA | cellular_component |
GO:0043407 | negative regulation of MAP kinase activity | IDA | biological_process |
GO:0005634 | nucleus | IEA | cellular_component |
GO:0032930 | positive regulation of superoxide anion generation | ISS | biological_process |
GO:0032872 | regulation of stress-activated MAPK cascade | ISS | biological_process |
GO:0035726 | common myeloid progenitor cell proliferation | ISS | biological_process |
GO:0051771 | negative regulation of nitric-oxide synthase biosy | IDA | biological_process |
GO:0035732 | nitric oxide storage | NAS | biological_process |
GO:0007417 | central nervous system development | TAS | biological_process |
GO:0005829 | cytosol | TAS | cellular_component |
GO:0044281 | small molecule metabolic process | TAS | biological_process |
GO:0043124 | negative regulation of I-kappaB kinase/NF-kappaB c | ISS | biological_process |
GO:0070373 | negative regulation of ERK1 and ERK2 cascade | IDA | biological_process |
GO:0070026 | nitric oxide binding | NAS | molecular_function |
GO:0005515 | protein binding | IPI | molecular_function |
GO:0000302 | response to reactive oxygen species | ISS | biological_process |
GO:0035731 | dinitrosyl-iron complex binding | IDA | molecular_function |